Curated News
By: NewsRamp Editorial Staff
August 10, 2026

Scinai Appoints Eran Kuratz to Lead Supply Chain and Business Processes

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Scinai expands CDMO capacity with Recipharm acquisition, strengthening its position in the biopharma market.
  • Eran Kuratz will oversee supply chain and business processes, leveraging 30 years of experience to optimize operations.
  • Scinai's expanded facilities in Israel can produce more therapies, potentially improving patient access to treatments.
  • Scinai's new site in Yavne will handle small-molecule APIs and sterile fill-and-finish, diversifying its capabilities.

Impact - Why it Matters

This appointment underscores Scinai's commitment to strengthening its CDMO operations, which are vital to its revenue and growth. With the recent acquisition of Recipharm Israel, the company is expanding its manufacturing capabilities, and Kuratz's expertise will help streamline operations, improve efficiency, and ensure robust supply chain management. For investors and clients, this signals a focus on operational excellence, which could lead to improved profitability and service reliability in the competitive biopharmaceutical manufacturing sector.

Summary

Scinai Immunotherapeutics (NASDAQ: SCNI) has announced the appointment of Eran Kuratz as head of supply chain and business process administration for its wholly owned subsidiary, Scinai Biopharma Services Ltd. Kuratz brings over 30 years of leadership and operational expertise in the pharmaceutical, biotechnology, medical-device, and industrial sectors. In his new role, he will oversee procurement, contracting, inventory management, logistics, budgeting, IT and business systems, cybersecurity, and cross-functional business processes. This strategic move follows Scinai's expansion of its contract development and manufacturing organization (CDMO) platform through the acquisition of Recipharm Israel in Q1 2026, which added a second development and manufacturing site in Yavne. Combined with its existing operations in Jerusalem, Scinai now offers a comprehensive range of capabilities, including biologics process development, aseptic manufacturing, sterile fill-and-finish, small-molecule API development and synthesis, analytical-method development, and GMP manufacturing.

Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies, with a pipeline licensed from the Max Planck Society and PinCell S.r.l. The company also operates its CDMO subsidiary, which serves biotech and pharma clients from its facilities in Israel. The appointment of Kuratz is expected to enhance operational efficiency and support the company's growth trajectory. For more details, the full press release is available at https://ibn.fm/d9ktl. InvestorWire, a specialized communications platform, syndicated this news, and it is part of the Dynamic Brand Portfolio @ IBN.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Scinai Appoints Eran Kuratz to Lead Supply Chain and Business Processes

blockchain registration record for this content.